Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
32.74
+0.78 (2.44%)
Oct 20, 2025, 1:29 PM EDT - Market open
Legend Biotech Revenue
Legend Biotech had revenue of $255.06M in the quarter ending June 30, 2025, with 36.74% growth. This brings the company's revenue in the last twelve months to $796.84M, up 74.75% year-over-year. In the year 2024, Legend Biotech had annual revenue of $627.24M with 119.97% growth.
Revenue (ttm)
$796.84M
Revenue Growth
+74.75%
P/S Ratio
7.37
Revenue / Employee
$305,419
Employees
2,609
Market Cap
6.04B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 627.24M | 342.10M | 119.97% |
Dec 31, 2023 | 285.14M | 168.14M | 143.70% |
Dec 31, 2022 | 117.01M | 48.18M | 70.00% |
Dec 31, 2021 | 68.83M | -6.17M | -8.23% |
Dec 31, 2020 | 75.00M | 13.20M | 21.36% |
Jan 1, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
LEGN News
- 9 days ago - US FDA adds boxed warning to J&J, Legend Biotech's cancer therapy - Reuters
- 14 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 5 weeks ago - Legend Biotech Corporation (LEGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Legend Biotech Appoints Carlos Santos as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Legend Biotech: Q2 Record Sales Undermined By Losses, Immature Pipeline - Rating Downgrade - Seeking Alpha
- 2 months ago - Legend Biotech Corporation (LEGN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Legend Biotech Reports Second Quarter 2025 Results and Recent Highlights - GlobeNewsWire
- 4 months ago - Legend Biotech Unveils Groundbreaking 5-Year Survival Data for CARVYKTI® in Multiple Myeloma at 2025 ASCO Annual Meeting - GlobeNewsWire